---
title: Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer
  and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial
date: '2024-01-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38175595/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240104170743&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: DETECT III is the first clinical study indicating that
  phenotyping of CTCs might have clinical utility for stratification of MBC cancer
  patients to HER2-targeting therapies. The OS benefit could be related to lapatinib,
  but further studies are required to prove this clinical observation. ClinicalTrials.gov
  Registration Number: ...'
disable_comments: true
---
CONCLUSIONS: DETECT III is the first clinical study indicating that phenotyping of CTCs might have clinical utility for stratification of MBC cancer patients to HER2-targeting therapies. The OS benefit could be related to lapatinib, but further studies are required to prove this clinical observation. ClinicalTrials.gov Registration Number: ...